In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Immune Response acquires T cell receptor technology
Immune Response Corporation not to proceed with HIV study
Immune Response receives two U.S. patents
The Immune Response Corporation announces payment from Agouron Pharmaceuticals
MERIX Bioscience Announces Agreement with Geron Corporation for Development of Cancer Vaccines
Immune Response licenses Hybridon's 2nd-generation CpG DNA adjuvant
Immune Response announces restructuring of license agreement
Crucell and Vaxin Announce PER.C6 Licensing Agreement
MaxCyte Technology Licensed For Use In Geron's Cancer Vaccines